Drug-related problems in patients with erectile dysfunctions and multiple comorbidities

Huri, Hasniza Zaman; Ling, Chui Fang; Razack, Azad Hassan Abdul

doi:10.2147/tcrm.s118010

Cited by 6 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study conducted in Norway yielded 6,158 DRPs detected among 2,465 elderly patients after medication review, with an average of 2.6 DRPs per patient 35. Another recent study related to DRPs in erectile dysfunction patients identified 244 DRPs in 200 patients, with an average of 1.2±2.1 DRPs in each patient 17. Discrepancies between these studies can be due to several factors, such as different interpretations of the problems by researchers, study design, and settings.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Drug-related problems in patients with rheumatoid arthritis</p>

Ning¹,

Huri²,

Yahya³

2019

TCRM

Self Cite

View full text Add to dashboard Cite

BackgroundRheumatoid arthritis (RA) patients are at risk of acquiring drug-related problems (DRPs). However, there has been a lack of studies on DRPs in patients with RA up to now.MethodThis retrospective study was conducted in a tertiary hospital in Malaysia from January 2012 to December 2017 with the purpose of assessing DRPs in RA patients and factors associated with its occurrence. A total of 200 patients who had received pharmacological treatment for RA were enrolled in this study. Assessment of DRPs was based on the Pharmaceutical Network Care Europe tool version 5.01.ResultsA total of 289 DRPs with an average of 1.5±1.0 problems per patient were identified, in which 78.5% of the population had at least one DRP. The most common DRPs encountered were adverse reactions (38.8%), drug interactions (33.6%), and drug-choice problems (14.5%). Factors that had significant association with the occurrence of DRPs were polypharmacy (P=0.003), multiple comorbidities (P=0.001), hyperlipidemia (P=0.009), osteo (P=0.040), and renal impairment (P=0.044). These data indicated that the prevalence of DRPs was high among RA patients.ConclusionEarly identification of types of DRPs and associated factors may enhance the prevention and management of RA.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In Malaysia, there have been studies done on DRPs in other diseases, including erectile dysfunction, benign prostatic hyperplasia, and diabetes mellitus. 17 – 19 However, there has been a lack of studies on DRPs in patients with RA up to now. Currently, there are very limited data on DRPs in patients with RA in Malaysia.…”

Section: Introductionmentioning

confidence: 99%

<p>Drug-related problems in patients with rheumatoid arthritis</p>

Ning¹,

Huri²,

Yahya³

2019

TCRM

Self Cite

View full text Add to dashboard Cite

show abstract

“…It should also include questions about the patient’s sexual history, preferences, expectations, and goals, as well as any psychosocial factors that may affect his sexual function or motivation. The patient’s medical history should be investigated, especially regarding any comorbidities or medications that may cause or contribute to ED [ 50 ]. The clinical history should be conducted in a respectful and empathic manner, using clear and non-judgmental language.…”

Section: Diagnosis Of Ed In Hfmentioning

confidence: 99%

Heart Failure and Erectile Dysfunction: a Review of the Current Evidence and Clinical Implications

Carella,

Forleo,

Stanca

et al. 2023

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review Heart failure (HF) and erectile dysfunction (ED) are two common conditions that affect millions of men worldwide and impair their quality of life. ED is a frequent complication of HF, as well as a possible predictor of cardiovascular events and mortality. ED deserves more attention from clinicians and researchers. Recent Findings The pathophysiology of ED in HF involves multiple factors, such as endothelial dysfunction, reduced cardiac output, neurohormonal activation, autonomic imbalance, oxidative stress, inflammation, and drug side effects. The diagnosis of ED in HF patients should be based on validated questionnaires or objective tests, as part of the routine cardiovascular risk assessment. The therapeutic management of ED in HF patients should be individualized and multidisciplinary, considering the patient’s preferences, expectations, comorbidities, and potential drug interactions. The first-line pharmacological treatment for ED in HF patients with mild to moderate symptoms (NYHA class I–II) is phosphodiesterase type 5 inhibitors (PDE5Is), which improve both sexual function and cardiopulmonary parameters. PDE5Is are contraindicated in patients who use nitrates or nitric oxide donors for angina relief, and these patients should be advised to avoid sexual activity or to use alternative treatments for ED. Non-pharmacological treatments for ED, such as psychotherapy or couples therapy, should also be considered if there are significant psychosocial factors affecting the patient’s sexual function or relationship. Summary This review aims to summarize the most recent evidence regarding the prevalence of ED, the pathophysiology of this condition with an exhaustive analysis of factors involved in ED development in HF patients, a thorough discussion on diagnosis and management of ED in HF patients, providing practical recommendations for clinicians.

show abstract